BRISBANE, Calif., May 9 /PRNewswire-FirstCall/ -- InterMune, Inc. today announced that Dan Welch, President and Chief Executive Officer of InterMune, will present at the Bank of America 2008 Health Care Conference in Las Vegas on May 14, 2008 at 9:20 a.m. PDT (12:20 p.m EDT).
To access a live audio webcast of the presentation, investors and other interested parties may log on to the investor relations page of InterMune's corporate website at http://www.intermune.com/. The company recommends logging on to the site 15 minutes prior to the start of the presentation in order to register or download any necessary software.
About InterMune
InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a research and development portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone for the treatment of patients with IPF and a research program focused on small molecules for pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) in Phase 1b, a second-generation HCV protease inhibitor research program, and a research program evaluating a new target in hepatology. For additional information about InterMune and its R&D pipeline, please visit http://www.intermune.com/.
InterMune, Inc.
